Literature DB >> 19002102

Cultured CD4T cells and primary human lymphocytes express hOATPs: intracellular accumulation of saquinavir and lopinavir.

O Janneh1, R C Hartkoorn, E Jones, A Owen, S A Ward, R Davey, D J Back, S H Khoo.   

Abstract

BACKGROUND AND
PURPOSE: Drug efflux tranporters (P-glycoprotein (P-gp), multidrug resistance-associated protein (MRP)) limit the cellular uptake of human immunodeficiency virus protease inhibitors but the contribution of influx transporters in cells that (over)express P-gp or MRP is less clear. Here, we studied the expression of one influx transporter system, human organic anion-transporting polypeptide (hOATP), in some T-cell lines (CEM, CEM(VBL), CEM(E1000)) and in peripheral blood mononuclear cells (PBMCs) and examined the effects of manipulation of influx/efflux transporters on the uptake of saquinavir and lopinavir. EXPERIMENTAL APPROACH: The expression of hOATPs was studied by PCR. We used hOATP substrate or inhibitor (estrone-3-sulphate (E-3-S) or montelukast, respectively) and inhibitors of P-gp (XR9576) and MRP (MK571 and frusemide) to study functional interactions between influx and efflux transporters in the uptake of saquinavir and lopinavir. Lipophilicity of the drugs was measured by octanol/saline partition coefficient. KEY
RESULTS: CEM cells, their variants and PBMCs express various hOATP isoforms, with OATP3A1 detected in all of the cells. MK571, XR9576 and frusemide increased the uptake of saquinavir and lopinavir. E-3-S and montelukast reduced the uptake of saquinavir and lopinavir in some, but not all, of the cells. Pretreatment of the cells with MK571, XR9576 or frusemide, followed by E-3-S co-incubation reduced the cellular accumulation of saquinavir and lopinavir. Lopinavir is much more lipophilic than saquinavir. CONCLUSIONS AND IMPLICATIONS: Human OATPs, MRP, P-gp and lipophilicity determine the cellular uptake and retention of saquinavir and lopinavir. These data may have important implications for drug-drug interactions, drug safety and efficacy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19002102      PMCID: PMC2597246          DOI: 10.1038/bjp.2008.320

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  32 in total

1.  Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes.

Authors:  E F Choo; B Leake; C Wandel; H Imamura; A J Wood; G R Wilkinson; R B Kim
Journal:  Drug Metab Dispos       Date:  2000-06       Impact factor: 3.922

2.  Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver.

Authors:  G A Kullak-Ublick; M G Ismair; B Stieger; L Landmann; R Huber; F Pizzagalli; K Fattinger; P J Meier; B Hagenbuch
Journal:  Gastroenterology       Date:  2001-02       Impact factor: 22.682

3.  The distribution of the anti-HIV drug, 2'3'-dideoxycytidine (ddC), across the blood-brain and blood-cerebrospinal fluid barriers and the influence of organic anion transport inhibitors.

Authors:  J E Gibbs; S A Thomas
Journal:  J Neurochem       Date:  2002-02       Impact factor: 5.372

Review 4.  Bile salt transporters.

Authors:  Peter J Meier; B Stieger
Journal:  Annu Rev Physiol       Date:  2002       Impact factor: 19.318

5.  Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine.

Authors:  George K Dresser; David G Bailey; Brenda F Leake; Ute I Schwarz; Paul A Dawson; David J Freeman; Richard B Kim
Journal:  Clin Pharmacol Ther       Date:  2002-01       Impact factor: 6.875

6.  P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir.

Authors:  M T Huisman; J W Smit; H R Wiltshire; R M Hoetelmans; J H Beijnen; A H Schinkel
Journal:  Mol Pharmacol       Date:  2001-04       Impact factor: 4.436

7.  Direct evidence that saquinavir is transported by multidrug resistance-associated protein (MRP1) and canalicular multispecific organic anion transporter (MRP2).

Authors:  Gregory C Williams; Angela Liu; Gregory Knipp; Patrick J Sinko
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

8.  P-Glycoprotein and transporter MRP1 reduce HIV protease inhibitor uptake in CD4 cells: potential for accelerated viral drug resistance?

Authors:  K Jones; P G Bray; S H Khoo; R A Davey; E R Meaden; S A Ward; D J Back
Journal:  AIDS       Date:  2001-07-27       Impact factor: 4.177

9.  Inhibition of P-glycoprotein and multidrug resistance-associated proteins modulates the intracellular concentration of lopinavir in cultured CD4 T cells and primary human lymphocytes.

Authors:  Omar Janneh; Elizabeth Jones; Becky Chandler; Andrew Owen; Saye H Khoo
Journal:  J Antimicrob Chemother       Date:  2007-09-21       Impact factor: 5.790

10.  Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs.

Authors:  Maarten T Huisman; Johan W Smit; Kristel M L Crommentuyn; Noam Zelcer; Hugh R Wiltshire; Jos H Beijnen; Alfred H Schinkel
Journal:  AIDS       Date:  2002-11-22       Impact factor: 4.177

View more
  18 in total

Review 1.  The role of transporters in the pharmacokinetics of orally administered drugs.

Authors:  Sarah Shugarts; Leslie Z Benet
Journal:  Pharm Res       Date:  2009-06-30       Impact factor: 4.200

2.  HIV-1 Alters Intestinal Expression of Drug Transporters and Metabolic Enzymes: Implications for Antiretroviral Drug Disposition.

Authors:  Olena Kis; Sumathi Sankaran-Walters; M Tozammel Hoque; Sharon L Walmsley; Satya Dandekar; Reina Bendayan
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

Review 3.  Pharmacokinetic and pharmacodynamic drug interactions between antiretrovirals and oral contraceptives.

Authors:  Victoria Tittle; Lauren Bull; Marta Boffito; Nneka Nwokolo
Journal:  Clin Pharmacokinet       Date:  2015-01       Impact factor: 6.447

4.  Concentration-dependent effects and intracellular accumulation of HIV protease inhibitors in cultured CD4 T cells and primary human lymphocytes.

Authors:  Omar Janneh; Patrick G Bray; Elizabeth Jones; Christoph Wyen; Peter Chiba; David J Back; Saye H Khoo
Journal:  J Antimicrob Chemother       Date:  2010-03-17       Impact factor: 5.790

Review 5.  Influence of drug transport proteins on the pharmacokinetics and drug interactions of HIV protease inhibitors.

Authors:  Latoya Griffin; Pieter Annaert; Kim L R Brouwer
Journal:  J Pharm Sci       Date:  2011-06-22       Impact factor: 3.534

6.  The accumulation and metabolism of zidovudine in 3T3-F442A pre-adipocytes.

Authors:  Omar Janneh; Andrew Owen; Patrick G Bray; David J Back; Munir Pirmohamed
Journal:  Br J Pharmacol       Date:  2009-12-10       Impact factor: 8.739

7.  Montelukast is a potent and durable inhibitor of multidrug resistance protein 2-mediated efflux of taxol and saquinavir.

Authors:  Upal Roy; Geetika Chakravarty; Kerstin Honer Zu Bentrup; Debasis Mondal
Journal:  Biol Pharm Bull       Date:  2009-12       Impact factor: 2.233

Review 8.  Cyanobacterial cyclopeptides as lead compounds to novel targeted cancer drugs.

Authors:  Ioannis Sainis; Demosthenes Fokas; Katerina Vareli; Andreas G Tzakos; Valentinos Kounnis; Evangelos Briasoulis
Journal:  Mar Drugs       Date:  2010-03-15       Impact factor: 5.118

9.  Intracellular 'boosting' of darunavir using known transport inhibitors in primary PBMC.

Authors:  Wai San Kwan; Omar Janneh; Ruben Hartkoorn; Becky Chandler; Saye Khoo; David Back; Andrew Owen
Journal:  Br J Clin Pharmacol       Date:  2009-09       Impact factor: 4.335

10.  Antiretroviral drug transporters and metabolic enzymes in human testicular tissue: potential contribution to HIV-1 sanctuary site.

Authors:  Yiying Huang; Md Tozammel Hoque; Mohammad-Ali Jenabian; Kishanda Vyboh; Sana-Kay Whyte; Nancy L Sheehan; Pierre Brassard; Maud Bélanger; Nicolas Chomont; Courtney V Fletcher; Jean-Pierre Routy; Reina Bendayan
Journal:  J Antimicrob Chemother       Date:  2016-04-13       Impact factor: 5.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.